Program

Wednesday, June 27

Welcome Reception

8:00 p.m.-9:30 p.m.

Thursday, June 28

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 1: Interrogating Pathways Using Small Molecules

Session Chairperson: Christina D. Smolke, Stanford University, Stanford, CA
8:00 a.m.-10:00 a.m.

Cancer dependencies defined by genomic alterations and targeted by small molecules
Stuart L. Schreiber, Broad Institute of MIT and Harvard, Cambridge, MA

Challenges in translating the cancer genome into impactful drugs
Peter G. Smith, H3 Biomedicine, Cambridge, MA

Breaking Lipinski's rule: Design of not-so-small orally bioavailable cyclic peptides
R. Scott Lokey, University of California, Santa Cruz, CA

In silico designed covalent peptidomimetic inhibitors (KPT-SINE) of CRM1 modulate tumor suppressor protein nuclear export and induce apoptosis in cancer cells *
William T. Senapedis, Jr., Karyopharm Therapeutics, Natick, MA

Break

10:00 a.m.-10:30 a.m.

Session 2: Signaling Pathways

Session Chairperson: R. Scott Lokey, University of California, Santa Cruz, CA
10:30 a.m.-12:30 p.m.

Network biology and drug discovery
James J. Collins, Howard Hughes Medical Institute and Boston University, Boston, MA

Systems approaches to using and optimizing anti-cancer drugs
Michael B. Yaffe, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA

Quantifying and perturbing protein dynamics in single cancer cells
Galit Lahav, Harvard Medical School, Boston, MA

A systems biology approach to elucidating the consequences of complex ternary interactions of heparin, FGF ligands, and FGF receptor on downstream signaling in NSCLC cells *
Diana H. Chai, Merrimack Pharmaceuticals, Cambridge, MA

Considering alternate signaling mechanisms models in extrinsic apoptosis using programmatic modeling approaches *
Carlos F. Lopez, Harvard Medical School, Boston, MA

Lunch on Own / Free Time

12:30 p.m.-1:30 p.m.

Poster Session

1:30 p.m.-3:30 p.m.

Session 3: Synthetic Chemical Biology

Session Chairperson: Brent R. Stockwell, Columbia University, New York, NY
3:30 p.m.-5:30 p.m.

Designing biological systems to report on disease
Pamela A. Silver, Harvard Medical School, Boston, MA

Changing chasses and inventing elements: Developing a combined systems biology and engineering approach to designing complex function in cells
Adam Arkin, Virtual Institute of Microbial Stress and Survival, Berkeley, CA

Designs synthetic regulator RNAs: New tools for temporal and spatial control in biological systems
Christina D. Smolke, Stanford University, Stanford, CA

Evening Off / Dinner on Own

5:30 p.m.-

Friday, June 29

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 4: Genome-wide SH/siRNA Screening

Session Chairperson: Andrea Califano, Columbia University, New York, NY
8:00 a.m.-10:00 a.m.

Genetic strategies for next generation of breast cancer therapies
Jose M. Silva, Columbia University, New York, NY

Functional genomics to identify cancer targets and resistance
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

Genetic approaches to cancer
Stephen J. Elledge, Harvard Medical School, Boston, MA

Reversal of glucocorticoid resistance by AKT inhibition in T-ALL *
Adolfo Ferrando, Columbia University, New York, NY

Break

10:00 a.m.-10:30 a.m.

Session 5: Systems Pharmacology and the LINCS Initiative

Session Chairperson: Jose M. Silva, Columbia University, New York, NY
10:30 a.m.-12:30 p.m.

Gene expression signatues in drug discovery
Todd R. Golub, Broad Institute of MIT and Harvard, Cambridge, MA

Interrogating gene regulatory networks to explore the boundary between chemistry and biology in cancer
Andrea Califano, Columbia University, New York, NY

Functionalization of the cancer genome
Gordon B. Mills, University of Texas MD Anderson Cancer Center, Houston, TX

The receptor tyrosine kinase layer of breast cancer cell lines is predictive of the response to therapeutic drugs *
Mario Niepel, Harvard Medical School, Boston, MA

A cooperative molecular response to combined mTOR/HDAC inhibition revealed by transcriptional co-expression analysis *
John K. Simmons, National Cancer Institute, Bethesda, MD

Lunch on Own / Free Time

12:30 p.m.-2:00 p.m.

Session 6: Sensing and Pertubing Pathways

Session Chairperson: Gordon B. Mills, University of Texas MD Anderson Cancer Center, Houston, TX
2:00 p.m.-4:30 p.m.

Probing cell death with small molecules
Brent R. Stockwell, Columbia University, New York, NY

Super-resolution fluorescence microscopy of cells and tissues
Xiaowei Zhuang, Harvard University and Howard Hughes Medical Institute, Cambridge, MA

TMP-Tag: A chemical surrogate to the fluorescent proteins for live cell imaging
Virginia W. Cornish, Columbia University, New York, NY

Predicting drug response from cancer cell lines
Adam A. Margolin, Broad Institute of MIT and Harvard, Cambridge, MA

Visualizing the dynamic and heterogeneous responses of single cells to inhibitors of the growth factor signaling network *
John Albeck, Harvard Medical School, Boston, MA

Network modeling of epithelial-to-mesenchymal transition in liver cancer metastasis *
Steven N. Steinway, Penn State College of Medicine, Hershey, PA

Evening Off / Dinner on Own

4:30 p.m.-

Saturday, June 30

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 7: Chemical Biology and Cancer

Session Chairperson: Virginia W. Cornish, Columbia University, New York, NY
8:00 a.m.-10:00 a.m.

Chemical inhibition of bromodomains
James E. Bradner, Dana-Farber Cancer Institute, Boston, MA

Targeting transcription factors with small molecules
Angela N. Koehler, Broad Institute of MIT and Harvard, Cambridge, MA

A genomics approach to discover small-molecule pertubagens of cancer cells
Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, MA

Investigating combinatorial ligand addiction provides insights into rational drug combinations in cancer therapy *
Emily A. Pace, Merrimack Pharmaceuticals, Inc., Cambridge, MA

Dissecting signaling transduction network to infer master regulators of non small cell lung cancer *
Mukesh Bansal, Columbia University, New York, NY

Break

10:00 a.m.-10:15 a.m.

Session 8: Integrative Chemical and Systems Biology

Session Chairperson: Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, MA
10:15 a.m.-12:15 p.m.

Small-molecule modulators of the Hedgehog signaling pathway
James K. Chen, Stanford University School of Medicine, Stanford, CA

Proteomic and knowledge-based identification of tumor suppressors and cancer targets
Peter K. Jackson, Genentech, Inc., South San Francisco, CA

General methods to conditionally regulate protein stability
Thomas J. Wandless, Stanford University, Stanford, CA

Cells decide between quiescence and proliferation upon exit from mitosis *
Sabrina L. Spencer, Stanford University, Stanford, CA

A model of HGF and EGF dual ligand stimulation in ACHN cells constructed with the aid of a novel model merging heuristic *
Andrew L. Matteson, New York University, New York, NY

Closing Remarks and Departure

12:15 p.m.-12:30 p.m.